|
WO2020174002A1
|
|
Improved stem cell populations for allogeneic therapy
|
|
US2017119682A1
|
|
Mesenchymal stem cell-derived exosomes and their uses
|
|
US2018318354A1
|
|
Mesenchymal stem cell-derived exosomes and their uses
|
|
CA2983950A1
|
|
Biomarkers for determining the clinical response to cell therapy
|
|
GB201604304D0
|
|
Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
|
|
US2017121685A1
|
|
Mesenchymal stem cell-derived exosomes and their uses
|
|
WO2016001845A1
|
|
Mesenchymal stromal cells for treating rheumatoid arthritis
|
|
US2016120910A1
|
|
Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
|
|
EP2972368A2
|
|
Lymphocyte biomarkers for determining the clinical response to cell therapy
|
|
GB201319004D0
|
|
Medical use
|
|
GB201311290D0
|
|
Medical use
|
|
EP2710122A1
|
|
Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
|
|
KR20140016933A
|
|
Cell populations having immunoregulatory activity, method for isolation and uses
|
|
KR20130118315A
|
|
Stem cell culture media and methods
|
|
HUE031921T2
|
|
Methods and compositions for use in cellular therapies
|
